The third line of treatment for metastatic prostate cancer patients: Option or strategy?

Giandomenico Roviello; Roberto Petrioli; Letizia Laera; Edoardo Francini

doi:10.1016/j.critrevonc.2015.04.010

The third line of treatment for metastatic prostate cancer patients: Option or strategy?

Crit Rev Oncol Hematol. 2015 Sep;95(3):265-71. doi: 10.1016/j.critrevonc.2015.04.010. Epub 2015 May 21.

Authors

Giandomenico Roviello¹, Roberto Petrioli², Letizia Laera², Edoardo Francini³

Affiliations

¹ Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100 Siena, Italy. Electronic address: giandomenicoroviello@hotmail.it.
² Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100 Siena, Italy.
³ Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Via del Policlinico 155, 00161 Roma, Italy.

PMID: 26052050
DOI: 10.1016/j.critrevonc.2015.04.010

Abstract

New agents for metastatic castration-resistant prostate cancer (CRPC) developed in the past 3 years include cabaziataxel (Cbz), abiraterone acetate (AA) and enzalutamide (E). In this review, the results of clinical studies in which one of these drugs is included as the third line of treatment are discussed. Our review suggests that AA and E have limited activity, while Cbz seems to retain its efficacy. Prospective studies that further examine sequential treatments are warranted.

Keywords: Abiraterone acetate; Cabazitaxel; Enzalutamide; Prostate cancer; Sequential therapy.

Publication types

Review

MeSH terms

Abiraterone Acetate / therapeutic use*
Benzamides
Humans
Male
Neoplasm Metastasis
Nitriles
Phenylthiohydantoin / analogs & derivatives*
Phenylthiohydantoin / therapeutic use
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / mortality
Prostatic Neoplasms, Castration-Resistant / pathology
Taxoids / therapeutic use*

Substances

Benzamides
Nitriles
Taxoids
Phenylthiohydantoin
cabazitaxel
enzalutamide
Abiraterone Acetate